Remove Communication Remove Insurance Coverage and Processing Remove Pharmaceutical Manufacturing
article thumbnail

Harbour BioMed partners Otsuka on new T-cell therapy

Pharmaceutical Technology

Otsuka Pharmaceutical president and representative director Makoto Inoue noted: “HBM7020 is expected to demonstrate efficacy in a broad range of autoimmune diseases in which B cells play a major role in disease pathogenesis, and we hope to contribute further to the field of specialised autoimmune diseases and thereby benefit patients.”

article thumbnail

NSW government invests $13.39m in life-changing therapies

Pharmaceutical Technology

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. We may still continue to send you service-related and other non-promotional communications. Editorial content is independently produced and follows the highest standards of journalistic integrity. Sign up for our daily news round-up!

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

FDA cell and gene therapy director exit increases ‘volatility’ for sector

Pharmaceutical Technology

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. We may still continue to send you service-related and other non-promotional communications. Editorial content is independently produced and follows the highest standards of journalistic integrity. Sign up for our daily news round-up!

article thumbnail

Bridging the gap: A comprehensive approach to social determinants of health

Pharmaceutical Technology

Better insights into how SDoH affects health can highlight the systemic influences that leave certain groups with worse health outcomes than others, despite similar health insurance coverage or access. For example, it’s important to consider whether someone has insurance (public or private), a job, and what their income may be.